Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies

Endothelial injury is the central factor in the events leading to thrombotic microangiopathy (TMA); however, the mechanisms involved are not fully understood. Here we investigate the role of neutrophils (PMNs) and of complement activation in inducing microvascular damage and loss of thromboresistance in TMA associated with ADAMTS-13 deficiency. PMNs isolated during the acute phase of the disease released excessive amounts of reactive-oxygen species (ROS), N-derived oxidants and proteinases and induced damage and thromboresistance loss in human microvascular endothelial cell line (HMEC-1) ex vivo. Endothelial cytotoxicity and thromboresistance loss was also induced by TMA serum. Complement-derived products were responsible for the above effects: in fact, TMA serum caused C3 and Membrane Attack Complex (MAC) deposition on HMEC-1 and its cytotoxic effect was abolished by complement inhibition. TMA serum caused surface expression of P-selectin on HMEC-1 which may promote PMN adhesion and resulted in increased PMN cytotoxicity, indicating that complement may have a role in PMN activation. In addition, TMA serum stimulated control PMNs to release ROS and proteinases, and to cause endothelial cell cytotoxicity. All of the above effects were abrogated by complement inactivation. These data document for the first time that complement-initiated PMN activation and endothelial injury may have a crucial role in microvascular thrombosis of TMA associated with ADAMTS-13 deficiency.

[1]  R. D. Situnayake,et al.  Further evidence of lipid peroxidation in post-enteropathic haemolytic-uraemic syndrome , 1991, Pediatric Nephrology.

[2]  P. Ward,et al.  Neutrophil Adhesion to Human Endothelial Cells is Induced by the Membrane Attack Complex: The Roles of P-Selectin and Platelet Activating Factor , 2004, Inflammation.

[3]  G. Remuzzi,et al.  Familial haemolytic uraemic syndrome and an MCP mutation , 2003, The Lancet.

[4]  J. Petriz,et al.  Plasma from patients with thrombotic thrombocytopenic purpura induces activation of human monocytes and polymorphonuclear neutrophils , 2003, British journal of haematology.

[5]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[6]  R. Smith,et al.  Targeting anticomplement agents. , 2002, Biochemical Society transactions.

[7]  T. Miyata,et al.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Perico,et al.  von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. , 2002, Blood.

[9]  Peter J. Smith,et al.  Human genetics: To clot or not , 2001, Nature.

[10]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[11]  G. Remuzzi,et al.  Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. , 2001, Blood.

[12]  G. Remuzzi,et al.  Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Rare manifestations of Russell’s viper (Daboia russelii) envenoming in Sri Lanka , 2021 .

[13]  R P McEver,et al.  Adhesive Interactions of Leukocytes, Platelets, and the Vessel Wall during Hemostasis and Inflammation , 2001, Thrombosis and Haemostasis.

[14]  G. Remuzzi,et al.  The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. , 2001, Journal of the American Society of Nephrology : JASN.

[15]  Blanchette,et al.  Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura , 1999, British journal of haematology.

[16]  B. Nilsson,et al.  Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets. , 1999, Journal of immunology.

[17]  B. Nilsson,et al.  Phosphorylation of plasma proteins with emphasis on complement component C3. , 1999, Molecular immunology.

[18]  G. Remuzzi,et al.  Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 1999, Journal of the American Society of Nephrology : JASN.

[19]  H. Tsai,et al.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. , 1998, The New England journal of medicine.

[20]  B. Lämmle,et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. , 1998, The New England journal of medicine.

[21]  Barry Halliwell,et al.  Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.

[22]  L. Horstman,et al.  Thrombotic thrombocytopenic purpura plasma enhances platelet–leucocyte interaction in vitro , 1998, British journal of haematology.

[23]  B. Nilsson,et al.  Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis. , 1997, Arthritis and rheumatism.

[24]  E. Jaffe,et al.  Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. , 1997, Blood.

[25]  G. Remuzzi,et al.  Increased nitric oxide formation in recurrent thrombotic microangiopathies: a possible mediator of microvascular injury. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  B. Evatt,et al.  Hemostatic properties of the SV-40 transfected human microvascular endothelial cell line (HMEC-1). A representative in vitro model for microvascular endothelium. , 1995, Thrombosis research.

[27]  B. Nilsson,et al.  Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b. , 1995, Journal of immunology.

[28]  P. Ward,et al.  C5a-induced expression of P-selectin in endothelial cells. , 1994, The Journal of clinical investigation.

[29]  U. Ryan,et al.  Superoxide dismutase mimetics inhibit neutrophil-mediated human aortic endothelial cell injury in vitro. , 1994, The Journal of biological chemistry.

[30]  A. Cheung,et al.  Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. , 1994, Journal of the American Society of Nephrology : JASN.

[31]  M. Oppermann,et al.  C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. , 1994, Blood.

[32]  T. Barratt,et al.  Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. , 1992, Kidney international.

[33]  D. Stroncek,et al.  Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis , 1992 .

[34]  D. Stroncek,et al.  Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. , 1992, Blood.

[35]  D. Milford,et al.  Prognostic markers in diarrhoea-associated haemolytic-uraemic syndrome: initial neutrophil count, human neutrophil elastase and von Willebrand factor antigen. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  K. Forsyth,et al.  NEUTROPHIL-MEDIATED ENDOTHELIAL INJURY IN HAEMOLYTIC URAEMIC SYNDROME , 1989, The Lancet.

[37]  D. V. Van Epps,et al.  Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes. , 1984, Journal of immunology.

[38]  M. Polley,et al.  The human complement system in thrombin-mediated platelet function , 1978, The Journal of experimental medicine.

[39]  Weisenburger Dd,et al.  Thrombotic thrombocytopenic purpura with C'3 vascular deposits: report of a case. , 1977 .

[40]  Miller He,et al.  Thrombotic thrombocytopenic purpura; report of a case. , 1954 .

[41]  R. Heffner,et al.  Thrombotic thrombocytopenic purpura. , 1954, New York state journal of medicine.